The Discontinuation Rate with Collagenase Clostridium Histolyticum for Peyronie's Disease in a High-Volume Practice is Unexpectedly High: Identifying Opportunities for Patient Care Improvement
Description
CONCLUSION: We present the largest series of patients to date dedicated to evaluation of CCH discontinuation. We find that up to 1/3 of patients who begin CCH injections will not complete the full treatment course. Understanding the reasons for
